CCS Research
CCS Publications
  • Kater AP, Tonino SH, Egle A, Ramsay AG. How does lenalidomide target the chronic lymphocytic leukemia microenvironment? Blood 2014;124:2184-9.

  • Egle A. Old and new news in CLL: "It's the pathway, stupid!". Blood 2014;124:989-90.

  • Aspalter M, Lechner M, Linni K, Hitzl W, Holzenbein T, Ofner D, et al. Morbidity after insertion of totally implantable venous access ports in oncological patients: results of a retrospective clinical study. The American surgeon 2014;80:204-7.

  • DeVries AF, Piringer G, Kremser C, Judmaier W, Saely CH, Lukas P, et al. Pretreatment evaluation of microcirculation by dynamic contrast-enhanced magnetic resonance imaging predicts survival in primary rectal cancer patients. International journal of radiation oncology, biology, physics 2014;90:1161-7.

  • Hartmann TN. CLL cells under flow. Blood 2014;123:3533-4.

  • Eisterer W, De Vries A, Ofner D, Rabl H, Koplmuller R, Greil R, et al. Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial. Anticancer research 2014;34:6767-73.

  • Burgstaller S, Bettelheim P, Krieger O, Machherndl-Spandl S, Nosslinger T, Pleyer L, et al. 10th anniversary of the Austrian MDS Platform: aims and ongoing projects. Wiener klinische Wochenschrift 2014.

  • Gangl O, Sahora K, Kornprat P, Margreiter C, Primavesi F, Bareck E, et al. Preparing for prospective clinical trials: a national initiative of an excellence registry for consecutive pancreatic cancer resections. World journal of surgery 2014;38:456-62.

  • Teperino R, Aberger F, Esterbauer H, Riobo N, Pospisilik JA. Canonical and non-canonical Hedgehog signalling and the control of metabolism. Seminars in cell & developmental biology 2014;33:81-92.

  • Putz EM, Hoelzl MA, Baeck J, Bago-Horvath Z, Schuster C, Reichholf B, et al. Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance. Cancers 2014;6:193-210.

  • Aberger F, Ruiz IAA. Context-dependent signal integration by the GLI code: the oncogenic load, pathways, modifiers and implications for cancer therapy. Seminars in cell & developmental biology 2014;33:93-104.

  • Lechner M, Fortelny R, Ofner D, Mayer F. Suspected inguinal hernias in pregnancy--handle with care! Hernia : the journal of hernias and abdominal wall surgery 2014;18:375-9.

  • Rendl G, Rettenbacher L, Holzmannhofer J, Datz L, Hauser-Kronberger C, Fastner G, et al. Assessment of response to neoadjuvant radiochemotherapy with F-18 FLT and F-18 FDG PET/CT in patients with rectal cancer. Annals of nuclear medicine 2014.

  • Ye X, Shokrollahi K, Rozen WM, Conyers R, Wright P, Kenner L, et al. Anaplastic large cell lymphoma (ALCL) and breast implants: Breaking down the evidence. Mutation research Reviews in mutation research 2014;762C:123-32.

  • Schwab C, Berry D, Rauch I, Rennisch I, Ramesmayer J, Hainzl E, et al. Longitudinal study of murine microbiota activity and interactions with the host during acute inflammation and recovery. The ISME journal 2014;8:1101-14.

  • Schlederer M, Mueller KM, Haybaeck J, Heider S, Huttary N, Rosner M, et al. Reliable quantification of protein expression and cellular localization in histological sections. PloS one 2014;9:e100822.

  • Rauch I, Hainzl E, Rosebrock F, Heider S, Schwab C, Berry D, et al. Type I interferons have opposing effects during the emergence and recovery phases of colitis. European journal of immunology 2014;44:2749-60.

  • Rao S, Tortola L, Perlot T, Wirnsberger G, Novatchkova M, Nitsch R, et al. A dual role for autophagy in a murine model of lung cancer. Nature communications 2014;5:3056.

  • Muller S, Chen Y, Ginter T, Schafer C, Buchwald M, Schmitz LM, et al. SIAH2 antagonizes TYK2-STAT3 signaling in lung carcinoma cells. Oncotarget 2014;5:3184-96.

  • Moti N, Malcolm T, Hamoudi R, Mian S, Garland G, Hook CE, et al. Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin. Oncogene 2014.

  • Leitner NR, Lassnig C, Rom R, Heider S, Bago-Horvath Z, Eferl R, et al. Inducible, dose-adjustable and time-restricted reconstitution of STAT1 deficiency in vivo. PloS one 2014;9:e86608.

  • Birner P, Bartsch R, Schreiber M, Dubsky P, Kenner L. New approaches for breast cancer: should Ret kinase be considered as a novel therapeutic target? Future oncology 2014;10:333-6.

  • Berghoff AS, Birner P, Streubel B, Kenner L, Preusser M. ALK gene aberrations and the JUN/JUNB/PDGFR axis in metastatic NSCLC. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2014;122:867-72.

  • Arab K, Park YJ, Lindroth AM, Schafer A, Oakes C, Weichenhan D, et al. Long noncoding RNA TARID directs demethylation and activation of the tumor suppressor TCF21 via GADD45A. Molecular cell 2014;55:604-14.

  • Park SL, Fesinmeyer MD, Timofeeva M, Caberto CP, Kocarnik JM, Han Y, et al. Pleiotropic associations of risk variants identified for other cancers with lung cancer risk: the PAGE and TRICL consortia. Journal of the National Cancer Institute 2014;106:dju061.

  • Reinmuth N, Kloos S, Warth A, Risch A, Muley T, Hoffmann H, et al. Insulin-like growth factor 1 pathway mutations and protein expression in resected non-small cell lung cancer. Human pathology 2014;45:1162-8.

  • Wang Y, McKay JD, Rafnar T, Wang Z, Timofeeva MN, Broderick P, et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nature genetics 2014;46:736-41.

  • Wrage M, Hagmann W, Kemming D, Uzunoglu FG, Riethdorf S, Effenberger K, et al. Identification of HERC5 and its potential role in NSCLC progression. International journal of cancer Journal international du cancer 2014.

  • Wagner A, Mayr C, Bach D, Illig R, Plaetzer K, Berr F, et al. MicroRNAs associated with the efficacy of photodynamic therapy in biliary tract cancer cell lines. International journal of molecular sciences 2014;15:20134-57.

  • Schaefer B, Steurer M, Glodny B, Neureiter D, Moser P, Dorn L, et al. First experience with brentuximab vedotin in posttransplant lymphoproliferative disorder after liver transplantation: complete remission followed by lethal sepsis. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2014;20:1145-8.

  • Behmueller R, Forstenlehner IC, Tenhaken R, Huber CG. Quantitative HPLC-MS analysis of nucleotide sugars in plant cells following off-line SPE sample preparation. Analytical and Bioanalytical Chemistry 2014;406:3229-37.

  • Forstenlehner IC, Holzmann J, Scheffler K, Wieder W, Toll H, Huber CG. A Direct-Infusion- and HPLC-ESI-Orbitrap-MS Approach for the Characterization of Intact PEGylated Proteins. Analytical Chemistry 2014;86:826-34.

  • Martano G, Bojaxhi E, Forstenlehner IC, Huber CG, Bresgen N, Eckl PM, et al. Validation and application of sub-2 mu m core-shell UHPLC-UV-ESI-Orbitrap MS for identification and quantification of beta-carotene and selected cleavage products with preceding solid-phase extraction. Analytical and Bioanalytical Chemistry 2014;406:2909-24.

  • Muth T, Weilnboeck L, Rapp E, Huber CG, Martens L, Vaudel M, et al. DeNovoGUI: An Open Source Graphical User Interface for de Novo Sequencing of Tandem Mass Spectra. Journal of proteome research 2014;13:1143-6.

  • Quint K, Stiel N, Neureiter D, Schlicker HU, Nimsky C, Ocker M, et al. The role of sphingosine kinase isoforms and receptors S1P1, S1P2, S1P3, and S1P5 in primary, secondary, and recurrent glioblastomas. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2014;35:8979-89.

  • Neureiter D, Jager T, Ocker M, Kiesslich T. Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects. World journal of gastroenterology : WJG 2014;20:7830-48.

  • Menendez-Castro C, Cordasic N, Neureiter D, Amann K, Marek I, Volkert G, et al. Underexpression of alpha8 integrin aggravates experimental atherosclerosis. The Journal of pathology 2014.

  • Mayr C, Neureiter D, Wagner A, Pichler M, Kiesslich T. The role of polycomb repressive complexes in biliary tract cancer. Expert opinion on therapeutic targets 2014:1-13.

  • Kiesslich T, Mayr C, Wachter J, Bach D, Fuereder J, Wagner A, et al. Activated hedgehog pathway is a potential target for pharmacological intervention in biliary tract cancer. Molecular and cellular biochemistry 2014;396:257-68.

  • Kemmerling R, Weyland D, Kiesslich T, Illig R, Klieser E, Jager T, et al. Robust linear regression model of Ki-67 for mitotic rate in gastrointestinal stromal tumors. Oncology letters 2014;7:745-9.

  • Jais A, Einwallner E, Sharif O, Gossens K, Lu TT, Soyal SM, et al. Heme oxygenase-1 drives metaflammation and insulin resistance in mouse and man. Cell 2014;158:25-40.

  • Gradwohl-Matis I, Illig R, Salmhofer H, Neureiter D, Brunauer A, Dunser MW. Fulminant systemic capillary leak syndrome due to C1 inhibitor deficiency complicating acute dermatomyositis: a case report. Journal of medical case reports 2014;8:28.

  • Behm B, Di Fazio P, Michl P, Neureiter D, Kemmerling R, Hahn EG, et al. Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation. Gut 2014.

  • Eckhard U, Huesgen PF, Brandstetter H, Overall CM. Proteomic protease specificity profiling of clostridial collagenases reveals their intrinsic nature as dedicated degraders of collagen. Journal of proteomics 2014;100:102-14.

  • Dockal M, Hartmann R, Fries M, Thomassen MC, Heinzmann A, Ehrlich H, et al. Small peptides blocking inhibition of factor Xa and tissue factor-factor VIIa by tissue factor pathway inhibitor (TFPI). The Journal of biological chemistry 2014;289:1732-41.

  • Dahms SO, Hardes K, Becker GL, Steinmetzer T, Brandstetter H, Than ME. X-ray structures of human furin in complex with competitive inhibitors. ACS chemical biology 2014;9:1113-8.

  • Eibl C, Hessenberger M, Wenger J, Brandstetter H. Structures of the NLRP14 pyrin domain reveal a conformational switch mechanism regulating its molecular interactions. Acta crystallographica Section D, Biological crystallography 2014;70:2007-18.

  • Deressa T, Stoecklinger A, Wallner M, Himly M, Kofler S, Hainz K, et al. Structural integrity of the antigen is a determinant for the induction of T-helper type-1 immunity in mice by gene gun vaccines against E. coli beta-galactosidase. PloS one 2014;9:e102280.

  • Guo S, Skala W, Magdolen V, Brandstetter H, Goettig P. Sweetened kallikrein-related peptidases (KLKs): glycan trees as potential regulators of activation and activity. Biological chemistry 2014;395:959-76.

  • Skala W, Utzschneider DT, Magdolen V, Debela M, Guo S, Craik CS, et al. Structure-Function Analyses of Human Kallikrein-related Peptidase 2 Establish the 99-Loop as Master Regulator of Activity. The Journal of biological chemistry 2014;289:34267-83.

  • Beisswenger M, Cabrele C. Self-recognition behavior of a helix-loop-helix domain by a fragment scan. Biochimica et biophysica acta 2014;1844:1675-83.

  • Cabrele C, Martinek TA, Reiser O, Berlicki L. Peptides Containing beta-Amino Acid Patterns: Challenges and Successes in Medicinal Chemistry. Journal of medicinal chemistry 2014;57:9718-39.

  • Gruber W, Frischauf A, Aberger F. An old friend with new skills: Imiquimod as novel inhibitor of Hedgehog signaling in basal cell carcinoma. Oncoscience 2014;1 (9), 567-573.

  • Stattner S, Primavesi F, Yip VS, Jones RP, Ofner D, Malik HZ, et al. Evolution of surgical microwave ablation for the treatment of colorectal cancer liver metastasis: review of the literature and a single centre experience. Surgery today 2014.

  • Schweigert M, Solymosi N, Dubecz A, Gonzalez MP, Stein HJ, Ofner D. One decade of experience with endoscopic stenting for intrathoracic anastomotic leakage after esophagectomy: brilliant breakthrough or flash in the pan? The American surgeon 2014;80:736-45.

  • Schweigert M, Solymosi N, Dubecz A, Fernandez MJ, Stadlhuber RJ, Ofner D, et al. Surgery for parapneumonic pleural empyema - What influence does the rising prevalence of multimorbidity and advanced age has on the current outcome? The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland 2014.

  • Schweigert M, Posada-Gonzalez M, Dubecz A, Ofner D, Muschweck H, Stein HJ. Recurrent oesophageal cancer complicated by tracheo-oesophageal fistula: improved palliation by means of parallel tracheal and oesophageal stenting. Interactive cardiovascular and thoracic surgery 2014;18:190-6.

  • Schweigert M, Giraldo Ospina CF, Solymosi N, Karmy-Jones R, Dubecz A, Fernandez MJ, et al. Emergent pneumonectomy for lung gangrene: does the outcome warrant the procedure? The Annals of thoracic surgery 2014;98:265-70.

  • Schweigert M, Dubecz A, Ofner D, Stein HJ. Gangrene of the oesophago-gastric junction caused by strangulated hiatal hernia: operative challenge or surgical dead end. Irish journal of medical science 2014;183:323-30.

  • Troppan KT, Schlick K, Deutsch A, Melchardt T, Egle A, Stojakovic T, et al. C-reactive protein level is a prognostic indicator for survival and improves the predictive ability of the R-IPI score in diffuse large B-cell lymphoma patients. British journal of cancer 2014;111:55-60.

  • Goldberg T, Hecht M, Hamp T, Karl T, Yachdav G, Ahmed N, et al. LocTree3 prediction of localization. Nucleic Acids Res 2014;42:W350-5.

  • Rebhandl S, Huemer M, Gassner FJ, Zaborsky N, Hebenstreit D, Catakovic K, et al. APOBEC3 signature mutations in chronic lymphocytic leukemia. Leukemia 2014;28:1929-32.

  • Melchardt T, Weiss L, Hufnagl C, Neureiter D, Kemmerling R, Morre P, et al. Treatment of aggressive B-cell lymphoma in elderly patients: influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics. Leukemia & lymphoma 2014:1-8.

  • Tassara M, Dohner K, Brossart P, Held G, Gotze K, Horst HA, et al. Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. Blood 2014;123:4027-36.

  • Melchardt T, Magnes T, Weiss L, Grundbichler M, Strasser M, Hufnagl C, et al. Liver toxicity during temozolomide chemotherapy caused by Chinese herbs. BMC Complement Altern Med 2014;14:115.

  • Girbl T, Lunzer V, Greil R, Namberger K, Hartmann TN. The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor. Transfusion 2014;54:2325-35.

  • Rebhandl S, Huemer M, Zaborsky N, Gassner FJ, Catakovic K, Felder TK, et al. Alternative splice variants of AID are not stoichiometrically present at the protein level in chronic lymphocytic leukemia. European journal of immunology 2014;44:2175-87.

  • Gassner FJ, Zaborsky N, Neureiter D, Huemer M, Melchardt T, Egle A, et al. Chemotherapy-induced augmentation of T cells expressing inhibitory receptors is reversed by treatment with lenalidomide in chronic lymphocytic leukemia. Haematologica 2014;99:67-9.

  • Pleyer L, Germing U, Sperr WR, Linkesch W, Burgstaller S, Stauder R, et al. Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leukemia research 2014;38:475-83.

  • Filipits M, Nielsen TO, Rudas M, Greil R, Stoger H, Jakesz R, et al. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. Clin Cancer Res 2014;20:1298-305.

  • Hofbauer SW, Krenn PW, Ganghammer S, Asslaber D, Pichler U, Oberascher K, et al. Tiam1/Rac1 signals contribute to the proliferation and chemoresistance, but not motility, of chronic lymphocytic leukemia cells. Blood 2014;123:2181-8.

  • Taylor N, Kern JM, Prammer W, Lang A, Haas B, Gisinger M, et al. Human immunodeficiency virus type 2 infections in Austria. Wiener klinische Wochenschrift 2014;126:212-6.

  • Hopfinger G, Nosslinger T, Lang A, Linkesch W, Melchardt T, Weiss L, et al. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. Annals of hematology 2014;93:459-62.

  • Grossinger EM, Weiss L, Zierler S, Rebhandl S, Krenn PW, Hinterseer E, et al. Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade. Leukemia 2014;28:954-8.

  • Taylor N, Haschke-Becher E, Greil R, Strasser M, Oberkofler H. Performance characteristics of the COBAS Ampliprep/COBAS TaqMan v2.0 and the Abbott RealTime hepatitis C assays - implications for response-guided therapy in genotype 1 infections. Antivir Ther 2014;19:449-54.

  • Gampenrieder SP, Romeder F, Muss C, Pircher M, Ressler S, Rinnerthaler G, et al. Hypertension as a predictive marker for bevacizumab in metastatic breast cancer: results from a retrospective matched-pair analysis. Anticancer research 2014;34:227-33.

  • Ludwig H, Kasparu H, Leitgeb C, Rauch E, Linkesch W, Zojer N, et al. Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma. Blood 2014;123:985-91.

  • Steger GG, Greil R, Lang A, Rudas M, Fitzal F, Mlineritsch B, et al. Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2014;25:366-71.

  • Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2014;25:339-45.

  • Heitzer E, Artl M, Filipits M, Resel M, Graf R, Weissenbacher B, et al. Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1. Mod Pathol 2014;27:906-15.

  • Weiss L, Melchardt T, Habringer S, Boekstegers A, Hufnagl C, Neureiter D, et al. Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2014;25:171-6.

  • Fiegl M, Stauder R, Steurer M, Mian M, Hopfinger G, Brychtova Y, et al. Alemtuzumab in chronic lymphocytic leukemia: final results of a large observational multicenter study in mostly pretreated patients. Annals of hematology 2014;93:267-77.

  • Brachtl G, Pinon Hofbauer J, Greil R, Hartmann TN. The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia. Annals of hematology 2014;93:361-74.

  • Melchardt T, Weiss L, Namberger K, Pretsch I, Hutter J, Rettenbacher L, et al. Pleural decortication of a marginal zone lymphoma. Annals of hematology 2014;93:1253-4.

  • Huemer F, Gampenrieder SP, Schlattau A, Greil R. Overcoming resistance against HER2-targeting agents in fifth-line therapy: is there still a place for bevacizumab in HER2+ breast cancer? Clin Breast Cancer 2014;14:e17-20.

  • Hohla F, Hopfinger G, Romeder F, Rinnerthaler G, Bezan A, Stattner S, et al. Female gender may predict response to FOLFIRINOX in patients with unresectable pancreatic cancer: a single institution retrospective review. International journal of oncology 2014;44:319-26.

  • Brodowicz T, Lang I, Kahan Z, Greil R, Beslija S, Stemmer SM, et al. Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses. British journal of cancer 2014;111:2051-7.

  • Melchardt T, Troppan K, Weiss L, Hufnagl C, Neureiter D, Trankenschuh W, et al. A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and beta -microglobulin. British journal of haematology 2014.

  • Huemer M, Rebhandl S, Zaborsky N, Gassner FJ, Hainzl S, Weiss L, et al. AID induces intraclonal diversity and genomic damage in CD86(+) chronic lymphocytic leukemia cells. European journal of immunology 2014;44:3747-57.

  • Benner A, Mansouri L, Rossi D, Majid A, Willander K, Parker A, et al. MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis. Haematologica 2014;99:1285-91.

  • Habringer S, Boekstegers A, Weiss L, Hopfinger G, Meissnitzer T, Melchardt T, et al. Kasabach-Merritt phenomenon in hepatic angiosarcoma. British journal of haematology 2014;167:716-8.

  • Schlick K, Troch M, Placher-Sorko G, Faber V, Neureiter D, Berghoff AS, et al. A patient diagnosed with BRAF-mutated non-small cell lung cancer and hairy cell leukemia: at last, which entity is really carrying the BRAF mutation? Annals of hematology 2014.

  • Kocher F, Pircher A, Mohn-Staudner A, Romeder F, Duller W, Steinmaurer M, et al. Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial). Lung cancer 2014;85:395-400.

  • Te Raa GD, Malcikova J, Mraz M, Trbusek M, Le Garff-Tavernier M, Merle-Beral H, et al. Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach. British journal of haematology 2014;167:565-9.

  • Pleyer L, Burgstaller S, Girschikofsky M, Linkesch W, Stauder R, Pfeilstocker M, et al. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Annals of hematology 2014;93:1825-38.

  • Hohla F, Winder T, Greil R, Rick FG, Block NL, Schally AV. Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives. World journal of gastroenterology : WJG 2014;20:6102-12.

  • Hutterer E, Asslaber D, Caldana C, Krenn PW, Zucchetto A, Gattei V, et al. CD18 (ITGB2) expression in chronic lymphocytic leukaemia is regulated by DNA methylation-dependent and -independent mechanisms. British journal of haematology 2014.

  • Eisterer W, A DEV, Ofner D, Rabl H, Koplmuller R, Greil R, et al. Preoperative Treatment with Capecitabine, Cetuximab and Radiotherapy for Primary Locally Advanced Rectal Cancer - A Phase II Clinical Trial. Anticancer research 2014;34:6767-73.

  • Ludwig H, Rauch E, Kuehr T, Adam Z, Weissmann A, Kasparu H, et al. Lenalidomide and dexamethasone for acute light chain-induced renal failure: a phase II study. Haematologica 2014.

  • Blank PR, Filipits M, Dubsky P, Gutzwiller F, Lux MP, Brase JC, et al. Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients. Pharmacoeconomics 2014.

  • Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2014.

Translational cancer research at CCS

Bench-to-bedside and bedside-to-bench work

The scientific strategy and conceptual organization of CCS allows both the validation of basic research findings in clinical settings (bench to bedside) and the detailed molecular analysis of clinical observations in predictive in vitro and in vivo model systems (bedside to bench). This bidirectional research strategy accelerates the discovery of novel and innovative therapeutic approaches for personalized cancer therapy. 

Funding & Support

Cancer Cluster Salzburg at SCRI

3rd Medical Department

Paracelsus Medical University Clinics Salzburg

Müllner Hauptstrasse 48, 5020 Salzburg, Austria

Email: ccs@sbg.ac.at

Cancer Cluster Salzburg at PLUS

Department of Biosciences

University of Salzburg

Hellbrunner Strasse 34, 5020 Salzburg, Austria

Email: ccs@sbg.ac.at